Immuneering Corp (IMRX)
1.54
+0.07
(+4.76%)
USD |
NASDAQ |
May 21, 15:35
Immuneering Cash from Operations (Quarterly): -15.49M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -15.49M |
December 31, 2023 | -11.78M |
September 30, 2023 | -12.03M |
June 30, 2023 | -10.75M |
March 31, 2023 | -14.42M |
December 31, 2022 | -11.75M |
September 30, 2022 | -10.62M |
June 30, 2022 | -9.449M |
March 31, 2022 | -12.28M |
Date | Value |
---|---|
December 31, 2021 | -9.239M |
September 30, 2021 | -9.035M |
June 30, 2021 | -6.437M |
March 31, 2021 | -6.140M |
December 31, 2020 | -5.453M |
September 30, 2020 | -3.486M |
June 30, 2020 | -3.367M |
March 31, 2020 | -2.314M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-15.49M
Minimum
Mar 2024
-2.314M
Maximum
Mar 2020
-9.061M
Average
-9.449M
Median
Jun 2022
Cash from Operations (Quarterly) Benchmarks
Geron Corp | -62.25M |
SELLAS Life Sciences Group Inc | -10.76M |
Elicio Therapeutics Inc | -12.12M |
ADMA Biologics Inc | -2.218M |
Outlook Therapeutics Inc | -19.27M |
Cash from Operations (Quarterly) Related Metrics
Cash from Investing (Quarterly) | 21.39M |
Cash from Financing (Quarterly) | 0.9799M |
Free Cash Flow | -50.39M |
Free Cash Flow Per Share (Quarterly) | -0.5287 |
Free Cash Flow Yield | -112.3% |